Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > ORGANIZATION
ORGANIZATION
- Astellas Becomes 1st Japan Maker to Join PhRMA Leadership
February 14, 2018
- Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
- “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018
- Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
January 30, 2018
- Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag
January 18, 2018
- Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
- Pharma Leaders Air Bleak Outlook on New PMP Scheme at New Year’s Reception
January 10, 2018
- JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
- Continued Discussions Needed for PMP-Eligible Products, Company Criteria: FPMAJ/JPMA
December 22, 2017
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
- Novo Pres. Bech Re-Elected as EFPIA Japan Chief
December 18, 2017
- GHIT Fund’s New 5-Year Strategic Plan Aims to Win Approval of 2 Products
December 12, 2017
- PhRMA/EFPIA to Govt: Make Major Changes to Drug Pricing Proposal, It Will Tarnish Japan’s Reputation
December 11, 2017
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
- Hodanren Petitions Health and Finance Ministers to “Abolish the Price Maintenance Premium”
November 22, 2017
- Patrik Jonsson to Remain PhRMA Japan Chief as Pricing Reform Debate Continues
November 20, 2017
- Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
- Discussions on PMP Should Go Beyond Its Scope: JMA’s Imamura
November 10, 2017
- Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…